New drug applications approved by US FDA as of 16 - 31 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 1 - 15 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The true prevalence of benign prostatic hyperplasia (BPH) in male populations has been difficult to estimate due to the lack of a standardized definition. However, the characteristic features of BPH – abnormal proliferation of stromal and epithelial prostatic cells – become more common in men with age. The following article highlights the benefits of dutasteride/tamsulosin (Duodart®, GlaxoSmithKline), a combination treatment consisting of two drugs with complementary mechanisms of action, in patients with BPH.
Older women with urinary incontinence symptoms exhibit a significant decline in standing balance, which may be associated with coinciding development of sarcopaenia, according to the secondary analysis of the Health, Aging and Body Composition Study.
Erectile dysfunction (ED) is a common condition defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.1 It is one of the most common complaints in men’s sexual medicine, affecting both physical and psychosocial health and having a significant impact on the patient and partner’s quality of life.1 Moreover, ED is commonly associated with other comorbid conditions, including hypertension, dyslipidaemia and diabetes mellitus.1
Evaluation of ED should include a detailed medical and sexual history of the patient. 1 A discussion of the patient and partner’s preference and treatment goals is essential to better tailor treatment and improve patient satisfaction and adherence to treatment.2 Lifestyle modification and management of risk factors should precede pharmacotherapy, while first-line treatment with oral phosphodiesterase type 5 inhibitors (PDE5i) is well established for the management of patients with ED.1